文献速递重症综合管理与镇静镇痛儿科与产科急症

儿童心脏骤停后冷应激激素FGF21与GDF-15的血清水平:单中心治疗性低温临床试验的二次分析

Serum levels of the cold stress hormones FGF21 and GDF-15 after cardiac arrest in infants and children enrolled in single center therapeutic hypothermia clinical trials.
PubMed 文献 · Resuscitation · 2021-11-22
一句话结论儿童心脏骤停后FGF21与GDF-15血清水平升高,FGF21在治疗性低温(33°C持续72小时)下升高更明显,GDF-15升高与院内死亡相关。

该研究为临床试验血清样本的二次分析,纳入68例患者(27例心脏骤停后[14例治疗性低温、13例常温]、9例儿童重症监护对照、32例健康对照),共检测144份样本。心脏骤停后初始FGF21和GDF-15中位水平均高于健康对照(392 vs 40 pg/mL,P<0.001;7089 vs 396 pg/mL,P<0.001)。心脏骤停组中,治疗性低温组FGF21从儿童重症监护第1天至第3天的中位变化高于常温组(231 vs -20 pg/mL,P<0.05),GDF-15随时间无差异。死亡患者GDF-15水平高于存活者(19450 vs 5337 pg/mL,P<0.05),FGF21与死亡无关。

要点

  • 儿童心脏骤停后初始FGF21中位水平392 pg/mL,高于健康对照40 pg/mL(P<0.001)。
  • 儿童心脏骤停后初始GDF-15中位水平7089 pg/mL,高于健康对照396 pg/mL(P<0.001)。
  • 治疗性低温(33°C持续72小时)组FGF21从儿童重症监护第1天至第3天中位变化231 pg/mL,常温组-20 pg/mL(P<0.05)。
  • GDF-15在死亡患者中位19450 pg/mL,高于存活者5337 pg/mL(P<0.05);FGF21与死亡率无关。

适用人群与场景

  • 儿童心脏骤停后患者(治疗性低温临床试验入组者),年龄为婴儿和儿童。
  • 对照包括儿童重症监护(PICU)患者和健康儿童。

处置流程与药物剂量

  • 治疗性低温方案为33°C持续72小时,于心脏骤停后<24小时、24小时、48小时、72小时检测血清FGF21和GDF-15。

研究设计与关键结果

  • 研究类型为临床试验血清样本的二次分析,共68例患者、144份样本(27例心脏骤停[14例治疗性低温、13例常温]、9例PICU对照、32例健康对照)。
  • 心脏骤停后初始FGF21中位水平392 pg/mL vs 健康对照40 pg/mL(P<0.001);初始GDF-15中位水平7089 pg/mL vs 健康对照396 pg/mL(P<0.001)。
  • 心脏骤停组中,FGF21从PICU第1天至第3天(温度控制72小时后)的中位变化治疗性低温组231 pg/mL vs 常温组-20 pg/mL(P<0.05);GDF-15随时间无差异。
  • 死亡的心脏骤停患者GDF-15中位水平19450 pg/mL vs 存活者5337 pg/mL(P<0.05);FGF21水平与死亡率无关。

证据类型、等级与局限

  • 证据类型:临床试验血清样本的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,儿童心脏骤停后FGF21和GDF-15血清水平升高,FGF21似乎受治疗性低温增强。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Fibroblast Growth Factor 21 (FGF21) and Growth Differentiation Factor-15 (GDF-15) are putative neuroprotective cold stress hormones (CSHs) provoked by cold exposure that may be age-dependent. We sought to characterize serum FGF21 and GDF-15 levels in pediatric cardiac arrest (CA) patients and their association with use of therapeutic hypothermia (TH).

METHODS: Secondary analysis of serum samples from clinical trials. We measured FGF21 and GDF-15 levels in pediatric patients post-CA and compared levels to both pediatric intensive care (PICU) and healthy controls. Post-CA, we compared normothermia (NT) vs TH (33 °C for 72 h) treated cohorts at < 24 h, 24 h, 48 h, 72 h, and examined the change in CSHs over 72 h. We also assessed association between hospital mortality and initial levels.

RESULTS: We assessed 144 samples from 68 patients (27 CA [14 TH, 13 NT], 9 PICU and 32 healthy controls). Median initial FGF21 levels were higher post-CA vs. healthy controls (392 vs. 40 pg/mL, respectively, P < 0.001). Median GDF-15 levels were higher post-CA vs. healthy controls (7,089 vs. 396 pg/mL, respectively, P < 0.001). In the CA group, the median change in FGF21 from PICU day 1-3 (after 72 h of temperature control), was higher in TH vs. NT (231 vs. -20 pg/mL, respectively, P < 0.05), with no difference in GDF-15 over time. Serum GDF-15 levels were higher in CA patients that died vs. survived (19,450 vs. 5,337 pg/mL, respectively, P < 0.05), whereas serum FGF21 levels were not associated with mortality.

CONCLUSION: Serum levels of FGF21 and GDF-15 increased after pediatric CA, and FGF21 appears to be augmented by TH.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Herrmann JR, Fink EL, Fabio A, et al. Serum levels of the cold stress hormones FGF21 and GDF-15 after cardiac arrest in infants and children enrolled in single center therapeutic hypothermia clinical trials. Resuscitation. 2021. PMID: 34822938. doi:10.1016/j.resuscitation.2021.11.016

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。